Can we select NSCLC patients for immune checkpoint therapy?

MSI and ICI efficacy

Bonneville – JCO Precision Oncol 2017 * Middha – JCO Precision Oncol 2017 * Haraldsdottir - JCO Precision Oncol 2017

MSI

(MANTIS software) in

3.8%

of 11,139 tumors (39 cancer types)

Best technique? IHC, PCR, NGS, others

With MSIsensor, MSI in 1.8% (20 tumor types)